Recent Quotes (30 days)

You have no recent quotes
chg | %

Transition Therapeutics Inc  

(Public, TSE:TTH)   Watch this stock  
Find more results for TTH
0.0000
- Close
TSE data delayed by 15 mins - Disclaimer
Currency in
Range     -
52 week 0.89 - 3.54
Open     -
Vol / Avg. 0.00/2,031.00
Mkt cap     -
P/E     -
Div/yield     -
EPS -1.39
Shares 38.80M
Beta     -
Inst. own     -
Sep 13, 2016
Q4 2016 Transition Therapeutics Inc Earnings Release (Estimated)
Aug 25, 2016
Transition Therapeutics Inc Extraordinary Shareholders Meeting
  

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -47.29% -86.61%
Return on average equity -58.00% -107.14%
Employees 18 -
CDP Score - -

Address

101 College St Suite 220
TORONTO, ON M5G 1L7
Canada
+1-416-2607770 (Phone)
+1-416-2602886 (Fax)

Website links

Description

Transition Therapeutics Inc. is a product-focused biopharmaceutical company. The Company's principal business activity is the researching and developing of therapeutic agents. The Company is developing therapeutics for central nervous system (CNS) and metabolic disease indications. The Company's technologies are focused on the treatment of agitation and aggression in Alzheimer's disease and diabetes. The Company's subsidiary, Transition Therapeutics Ireland Limited (Transition Ireland), is developing two drug candidates: neuropsychiatric candidate ELND005 and androgen deficiency candidate TT701. The Company's subsidiary, Waratah Pharmaceuticals Inc. (Waratah), is developing diabetes drug candidate TT401. The Company's other two entities provide development services in support of the clinical and non-clinical activities of Transition Ireland and Waratah.